Article title: Efficacy and safety of peficitinib in rheumatoid arthritis

Author: Yuko Kaneko

Journal:Modern Rheumatology

DOI:https://www.tandfonline.com/doi/full/10.1080/14397595.2020.1794103

Please note the following correction to Figure 2.

The ACR50 achievement of the RAJ4 study was depicted incorrectly.

The corrected Figure 2 is given below.

ACR50 achievement of placebo and each peficitinib dose in the five randomized, placebo-controlled trials. RA21 and RA22 were global phase 2b trials. RAJ1 and RAJ4 were conducted in Japan, and RAJ3 was conducted in Japan, Korea, and Taiwan.
Figure 2.

ACR50 achievement of placebo and each peficitinib dose in the five randomized, placebo-controlled trials. RA21 and RA22 were global phase 2b trials. RAJ1 and RAJ4 were conducted in Japan, and RAJ3 was conducted in Japan, Korea, and Taiwan.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)